Radium-223 in prostate cancer
In a phase 3 trial in 921 men with castration-resistant prostate cancer and bone metastases, the alpha emitter radium-223 improved median overall survival to 14.9 months versus 11.3 months with placebo.
Built / tested: radium-223 dichloride
As reported in: Parker, Nilsson, Heinrich et al. (2013). Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer. New England Journal of Medicine. doi:10.1056/nejmoa1213755
Abstract only